Literature DB >> 22737267

Maspin reprograms the gene expression profile of prostate carcinoma cells for differentiation.

M Margarida Bernardo1, Yonghong Meng, Jaron Lockett, Gregory Dyson, Alan Dombkowski, Alexander Kaplun, Xiaohua Li, Shuping Yin, Sijana Dzinic, Mary Olive, Ivory Dean, David Krass, Kamiar Moin, R Daniel Bonfil, Michael Cher, Wael Sakr, Shijie Sheng.   

Abstract

Maspin is an epithelial-specific tumor suppressor gene. Previous data suggest that maspin expression may redirect poorly differentiated tumor cells to better differentiated phenotypes. Further, maspin is the first and only endogenous polypeptide inhibitor of histone deacetylase 1 (HDAC1) identified thus far. In the current study, to address what central program of tumor cell redifferentiation is regulated by maspin and how tumor microenvironments further define the effects of maspin, we conducted a systematic and extensive comparison of prostate tumor cells grown in 2-dimensional culture, in 3-dimensional collagen I culture, and as in vivo bone tumors. We showed that maspin was sufficient to drive prostate tumor cells through a spectrum of temporally and spatially polarized cellular processes of redifferentiation, a reversal of epithelial-to-mesenchymal transition (EMT). Genes commonly regulated by maspin were a small subset of HDAC target genes that are closely associated with epithelial differentiation and TGFβ signaling. These results suggest that a specific endogenous HDAC inhibitor may regulate one functionally related subset of HDAC target genes, although additional maspin-induced changes of gene expression may result from tumor interaction with its specific microenvironments. Currently, EMT is recognized as a critical step in tumor progression. To this end, our current study uncovered a link between maspin and a specific mechanism of prostate epithelial differentiation that can reverse EMT.

Entities:  

Keywords:  cell differentiation; microarray analysis; organotypic model

Year:  2011        PMID: 22737267      PMCID: PMC3379563          DOI: 10.1177/1947601912440170

Source DB:  PubMed          Journal:  Genes Cancer        ISSN: 1947-6019


  87 in total

Review 1.  Tumor suppressive maspin and epithelial homeostasis.

Authors:  Jaron Lockett; Shuping Yin; Xiaohua Li; Yonghong Meng; Shijie Sheng
Journal:  J Cell Biochem       Date:  2006-03-01       Impact factor: 4.429

2.  HDAC1 inhibition by maspin abrogates epigenetic silencing of glutathione S-transferase pi in prostate carcinoma cells.

Authors:  Xiaohua Li; Alexander Kaplun; Fulvio Lonardo; Elisabeth Heath; Fazlul H Sarkar; Jonathan Irish; Wael Sakr; Shijie Sheng
Journal:  Mol Cancer Res       Date:  2011-05-26       Impact factor: 5.852

Review 3.  Basement membrane matrix (BME) has multiple uses with stem cells.

Authors:  Irina Arnaoutova; Jay George; Hynda K Kleinman; Gabriel Benton
Journal:  Stem Cell Rev Rep       Date:  2012-03       Impact factor: 5.739

4.  HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT.

Authors:  Francesca Bruzzese; Alessandra Leone; Monia Rocco; Carmine Carbone; Geny Piro; Michele Caraglia; Elena Di Gennaro; Alfredo Budillon
Journal:  J Cell Physiol       Date:  2011-09       Impact factor: 6.384

5.  Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy.

Authors:  Yuting Sun; Bu-Er Wang; Kevin G Leong; Peng Yue; Li Li; Suchit Jhunjhunwala; Darrell Chen; Kyounghee Seo; Zora Modrusan; Wei-Qiang Gao; Jeffrey Settleman; Leisa Johnson
Journal:  Cancer Res       Date:  2011-11-22       Impact factor: 12.701

6.  Maspin, the molecular bridge between the plasminogen activator system and beta1 integrin that facilitates cell adhesion.

Authors:  Michael P Endsley; Yanqiu Hu; Yong Deng; Xiaolin He; Debra J Warejcka; Sally S Twining; Steven L Gonias; Ming Zhang
Journal:  J Biol Chem       Date:  2011-05-23       Impact factor: 5.157

Review 7.  Bone metastasis in prostate cancer: emerging therapeutic strategies.

Authors:  Justin Sturge; Matthew P Caley; Jonathan Waxman
Journal:  Nat Rev Clin Oncol       Date:  2011-05-10       Impact factor: 66.675

8.  Nuclear localization of maspin is essential for its inhibition of tumor growth and metastasis.

Authors:  Brigitte Goulet; Wendy Kennette; Amber Ablack; Carl O Postenka; M Nicole Hague; Joe S Mymryk; Alan B Tuck; Vincent Giguère; Ann F Chambers; John D Lewis
Journal:  Lab Invest       Date:  2011-04-18       Impact factor: 5.662

Review 9.  Cancer to bone: a fatal attraction.

Authors:  Katherine N Weilbaecher; Theresa A Guise; Laurie K McCauley
Journal:  Nat Rev Cancer       Date:  2011-05-19       Impact factor: 60.716

10.  Misregulated E-cadherin expression associated with an aggressive brain tumor phenotype.

Authors:  Laura J Lewis-Tuffin; Fausto Rodriguez; Caterina Giannini; Bernd Scheithauer; Brian M Necela; Jann N Sarkaria; Panos Z Anastasiadis
Journal:  PLoS One       Date:  2010-10-27       Impact factor: 3.240

View more
  23 in total

Review 1.  The Opportunity of Precision Medicine for Breast Cancer With Context-Sensitive Tumor Suppressor Maspin.

Authors:  Margarida M Bernardo; Sijana H Dzinic; Maria J Matta; Ivory Dean; Lina Saker; Shijie Sheng
Journal:  J Cell Biochem       Date:  2017-03-21       Impact factor: 4.429

2.  An Essential Role of Maspin in Embryogenesis and Tumor Suppression.

Authors:  Sijana H Dzinic; M Margarida Bernardo; Xiaohua Li; Rodrigo Fernandez-Valdivia; Ye-Shih Ho; Qing-Sheng Mi; Sudeshna Bandyopadhyay; Fulvio Lonardo; Semir Vranic; Daniel S M Oliveira; R Daniel Bonfil; Gregory Dyson; Kang Chen; Almasa Omerovic; Xiujie Sheng; Xiang Han; Dinghong Wu; Xinling Bi; Dzenana Cabaravdic; Una Jakupovic; Marian Wahba; Aaron Pang; Deanna Harajli; Wael A Sakr; Shijie Sheng
Journal:  Cancer Res       Date:  2016-12-06       Impact factor: 12.701

Review 3.  Tumor suppressor maspin as a rheostat in HDAC regulation to achieve the fine-tuning of epithelial homeostasis.

Authors:  Alexander Kaplun; Sijana Dzinic; M Bernardo; Shijie Sheng
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2012       Impact factor: 1.807

Review 4.  Primary ovarian insufficiency in classic galactosemia: current understanding and future research opportunities.

Authors:  Mili Thakur; Gerald Feldman; Elizabeth E Puscheck
Journal:  J Assist Reprod Genet       Date:  2017-09-20       Impact factor: 3.412

5.  Maspin Expression in Prostate Tumor Cells Averts Stemness and Stratifies Drug Sensitivity.

Authors:  M Margarida Bernardo; Alexander Kaplun; Sijana H Dzinic; Xiaohua Li; Jonathan Irish; Adelina Mujagic; Benjamin Jakupovic; Jessica B Back; Eric Van Buren; Xiang Han; Ivory Dean; Yong Q Chen; Elisabeth Heath; Wael Sakr; Shijie Sheng
Journal:  Cancer Res       Date:  2015-07-24       Impact factor: 12.701

6.  Monitoring Tumor Response After Histone Deacetylase Inhibitor Treatment Using 3'-Deoxy-3'-[18F]-fluorothymidine PET.

Authors:  Pei-Chia Chan; Chun-Yi Wu; Lin-Shan Chou; Chung-Hsien Ho; Chi-Wei Chang; Shih-Hwa Chiou; Wuu-Jyh Lin; Fu-Du Chen; C Allen Chang; Jeng-Jong Hwang; Ren-Shyan Liu; Hsin-Ell Wang
Journal:  Mol Imaging Biol       Date:  2015-06       Impact factor: 3.488

7.  Bacterial Lipopolysaccharide Augmented Malignant Transformation and Promoted the Stemness in Prostate Cancer Epithelial Cells.

Authors:  Sijie Tang; Xueqi Lian; Huiying Cheng; Jiaqian Guo; Daguang Ni; Can Huang; Xiang Gu; Hong Meng; Jiajia Jiang; Xiaohua Li
Journal:  J Inflamm Res       Date:  2021-11-09

Review 8.  Tackling tumor heterogeneity and phenotypic plasticity in cancer precision medicine: our experience and a literature review.

Authors:  Shijie Sheng; M Margarida Bernardo; Sijana H Dzinic; Kang Chen; Elisabeth I Heath; Wael A Sakr
Journal:  Cancer Metastasis Rev       Date:  2018-12       Impact factor: 9.264

Review 9.  Tumor suppressor maspin as a modulator of host immune response to cancer.

Authors:  Sijana H Dzinic; Maria M Bernardo; Daniel S M Oliveira; Marian Wahba; Wael Sakr; Shijie Sheng
Journal:  Bosn J Basic Med Sci       Date:  2015-10-25       Impact factor: 3.363

10.  A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study.

Authors:  Manish K Thakur; Lance K Heilbrun; Shijie Sheng; Mark Stein; Glenn Liu; Emmanuel S Antonarakis; Ulka Vaishampayan; Sijana H Dzinic; Xiaohua Li; Stacy Freeman; Daryn Smith; Elisabeth I Heath
Journal:  Invest New Drugs       Date:  2015-11-18       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.